Bowl of Hope, Bucket of Hype?

When a research team led by Ingo Potrykus of the Swiss Federal Institute of Technology in Zurich and Peter Beyer of the University of Freiburg in Germany announced last year that they had produced beta carotene, or provitamin A, in rice grains,1 the news created quite a stir.2 For one thing, getting "golden rice," as it was quickly dubbed (for its color, not its monetary value) required a biotech tour de force. Potrykus and Beyer inserted two genes from daffodil and one from a bacterium into ri

Written byBarry Palevitz
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Activists opposed to genetically modified (GM) foods lost little time responding. Potrykus and Beyer were attacked for the way they worked with companies to make seed available to the poor. Then, in February, Greenpeace got to the very germ of golden rice's existence. According to the organization's calculations, an adult "would have to eat around 9 kg of cooked rice daily to satisfy his/her daily need of vitamin A." That's about 20 pounds--clearly an unrealistic amount. In other words, Greenpeace argued, golden rice was little more than "fool's gold."

The Guardian in England soon picked up Greenpeace's argument, as did the New York Times on March 4, when op-ed columnist Michael Pollan faulted "the great yellow hype" given golden rice by industry advocates. In a letter to the London Independent, Benedikt Haerlin, Greenpeace coordinator in Berlin, refused to rule out direct action against test plants. Like rice at a wedding, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies